| First Author | Chou C | Year | 2022 |
| Journal | Nature | Volume | 605 |
| Issue | 7908 | Pages | 139-145 |
| PubMed ID | 35444279 | Mgi Jnum | J:330253 |
| Mgi Id | MGI:7367059 | Doi | 10.1038/s41586-022-04632-1 |
| Citation | Chou C, et al. (2022) Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature 605(7908):139-145 |
| abstractText | Cellular transformation induces phenotypically diverse populations of tumour-infiltrating T cells(1-5), and immune checkpoint blockade therapies preferentially target T cells that recognize cancer cell neoantigens(6,7). Yet, how other classes of tumour-infiltrating T cells contribute to cancer immunosurveillance remains elusive. Here, in a survey of T cells in mouse and human malignancies, we identified a population of alphabeta T cell receptor (TCR)-positive FCER1G-expressing innate-like T cells with high cytotoxic potential(8) (ILTCKs). These cells were broadly reactive to unmutated self-antigens, arose from distinct thymic progenitors following early encounter with cognate antigens, and were continuously replenished by thymic progenitors during tumour progression. Notably, expansion and effector differentiation of intratumoural ILTCKs depended on interleukin-15 (IL-15) expression in cancer cells, and inducible activation of IL-15 signalling in adoptively transferred ILTCK progenitors suppressed tumour growth. Thus, the antigen receptor self-reactivity, unique ontogeny, and distinct cancer cell-sensing mechanism distinguish ILTCKs from conventional cytotoxic T cells, and define a new class of tumour-elicited immune response. |
